Everything you always wanted to know about CADY-mediated siRNA delivery* (* But afraid to ask)

Current Pharmaceutical Design

Volumn 19, Issue 16, 2013, Pages 2869-2877

  Konate, Karidia ^a   Rydstrom, Anna ^a   Divita, Gilles ^a   Deshayes, Sebastien ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

CADY; Cell penetrating peptide; Direct translocation; Non covalent delivery; SiRNA

Indexed keywords

CADY PEPTIDE; CELL PENETRATING PEPTIDE; MEMBRANE PHOSPHOLIPID; NANOPARTICLE; PEPTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADHERENT CELL; ARTIFICIAL MEMBRANE; CELL ENERGY; CELL MEMBRANE; CELL SURFACE; CIRCULAR DICHROISM; CONFORMATION; CONFORMATIONAL TRANSITION; DRUG DELIVERY SYSTEM; FLUORESCENCE POLARIZATION; HUMAN; IC 50; INTERNALIZATION; LIPID MONOLAYER; MAMMAL CELL; MEMBRANE VESICLE; MOLECULAR MODEL; NANOMEDICINE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; REVIEW; SIMIAN VIRUS 40; STATIC ELECTRICITY; T LYMPHOCYTE; TISSUE SPECIFICITY; ZETA POTENTIAL;

ANIMALS; CELL-PENETRATING PEPTIDES; GENE TRANSFER TECHNIQUES; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; NANOPARTICLES; PEPTIDES; RNA, SMALL INTERFERING; STATIC ELECTRICITY;

EID: 84878631538     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319160004     Document Type: Review

References (71)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
2. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004; 3: 318-29.
3. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012; 19: 60-71.
4. De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6: 443-53.
5. Castanotto D, Rossi JJ. The promises and pitfalls of RNAinterference-based therapeutics. Nature 2009; 457: 426-33.
6. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8: 129-38.
7. Sibley CR, Seow Y, Wood MJ. Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 2010; 18: 466-76.
8. Zhang S, Zhao Y, Zhi D, Zhang S. Non-viral vectors for the mediation of RNAi. Bioorg Chem 2012; 40: 10-8.
9. Lee SK, Siefert A, Beloor J, Fahmy TM, Kumar P. Cell-specific siRNA delivery by peptides and antibodies. Methods Enzymol 2012; 502: 91-122.
10. Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnol Adv 2011; 29: 402-17.
11. Gao K, Huang L. Nonviral methods for siRNA delivery. Mol Pharm 2009; 6: 651-8.
12. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008; 36: 4158-71.
13. Eguchi A, Dowdy SF. siRNA delivery using peptide transduction domains. Trends Pharmacol Sci 2009; 30: 341-5.
14. Järver P, Mäger I, Langel Ü. In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol Sci 2010; 31: 528-35.
15. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009; 157: 195-206.
16. Zorko M, Langel Ü. Cell-penetrating peptides: mechanism and kinetics of cargo delivery, Adv Drug Deliv Rev 2005; 57: 529-45.
17. El-Andaloussi S, Holm T, Langel Ü. Cell-penetrating peptides:mechanism and applications, Curr Pharm Design 2005; 11: 3597-611
18. Murriel CL, Dowdy SF. Influence of protein transduction domains on intracellular delivery of macromolecules, Expert Opin Drug Deliv 2006; 3: 739-46.
19. Morris MC, Deshayes S, Heitz F, Divita G. Cell-penetrating peptides: from molecular mechanisms to therapeutics, Biol Cell 2008; 100: 201-17.
20. Crombez L, Morris MC, Deshayes S, Heitz F, Divita G. Peptidebased nanoparticle for ex vivo and in vivo drug delivery, Curr Pharm Des 2008; 14: 3656-65.
21. Mano M, Teodósio C, Paiva A, Simões S, Pedroso de Lima MC. On the mechanisms of the internalization of S4(13)-PV cellpenetrating peptide, Biochem J 2005; 390: 603-12.
22. Crombez L, Aldrian-Herrada G, Konate K, et al. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 2009; 17: 95-103.
23. Konate K, Crombez L, Deshayes S, et al. Insight into the cellular uptake mechanism of a secondary amphipathic cell-penetrating peptide for siRNA delivery. Biochemistry 2010; 49: 3393-402.
24. Rydström A, Deshayes S, Konate K, et al. Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PLoS One 2011; 6: e25924.
25. Crombez L, Divita G. A non-covalent peptide-based strategy for siRNA delivery. Methods Mol Biol 2011; 683: 349-60.
26. Deshayes S, Konate K, Rydström A, et al. Self-Assembling Peptide-Based Nanoparticles for siRNA Delivery in Primary Cell Lines. Small 2012; 8: 2184-8.
27. Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009; 27: 567-71.
28. Andaloussi SE, Lehto T, Mäger I, et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 2011; 39: 3972-87.
29. Lam JK, Liang W, Lan Y, et al. Effective endogenous gene silencing mediated by pH responsive peptides proceeds via multiple pathways. J Control Release 2012; 158: 293-303.
30. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 1997; 25: 2730-6.
31. Morris MC, Chaloin L, Méry J, Heitz F, Divita G. A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res 1999; 27: 3510-7.
32. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19:1173-6.
33. Deshayes S, Konate K, Aldrian G, Crombez L, Heitz F, Divita G. Structural polymorphism of non-covalent peptide-based delivery systems: highway to cellular uptake. Biochim Biophys Acta 2010; 1798: 2304-14.
34. Kalderon D, Richardson WD, Markham AF, Smith AE. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature 1984; 311: 33-8.
35. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003; 31: 2717-24.
36. Méry J, Granier C, Juin M, Brugidou J. Disulfide linkage to polyacrylic resin for automated Fmoc peptide synthesis. Immunochemical applications of peptide resins and mercaptoamide peptides. Int J Pept Protein Res 1993; 42: 44-52.
37. Rittner K, Benavente A, Bompard-Sorlet A, et al. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther 2002; 5: 104-14.
38. Gottschalk S, Sparrow JT, Hauer J, et al. A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther 1996; 3: 448-57.
39. Eiríksdóttir E, Konate K, Langel U, Divita G, Deshayes S. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim Biophys Acta 2010; 1798: 1119-28.
40. Crowet JM, Lins L, Deshayes S, et al. Modeling of non-covalent complexes of the cell-penetrating peptide CADY and its siRNA cargo. Biochim Biophys Acta 2013; 1828: 499-509.
41. Zachowski A. Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem J 1993; 294: 1-14.
42. Magzoub M, Gräslund A. Cell-penetrating peptides: from inception to application. Q Rev Biophys 2004; 37: 147-95.
43. Peetla C, Stine A, Labhasetwar V. Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol Pharm 2009; 6: 1264-76.
44. Brockman H. Lipid monolayers: why use half a membrane to characterize protein-membrane interactions? Curr Opin Struct Biol 1999; 9: 438-43.
45. Maget-Dana R. The monolayer technique: a potent tool for studying the interfacial properties of antimicrobial and membrane-lytic peptides and their interactions with lipid membranes. Biochim Biophys Acta 1999; 1462: 109-40.
46. Calvez P, Bussières S, Eric Demers, Salesse C. Parameters modulating the maximum insertion pressure of proteins and peptides in lipid monolayers. Biochimie 2009; 91: 718-33.
47. Magzoub M, Eriksson LE, Gräslund A. Conformational states of the cell-penetrating peptide penetratin when interacting with phospholipid vesicles: effects of surface charge and peptide concentration. Biochim Biophys Acta 2002; 1563: 53-63.
48. Persson D, Thorén PE, Herner M, Lincoln P, Nordén B. Application of a novel analysis to measure the binding of the membranetranslocating peptide penetratin to negatively charged liposomes. Biochemistry 2003; 42: 421-9.
49. Thorén PE, Persson D, Esbjörner EK, Goksör M, Lincoln P, Nordén B. Membrane binding and translocation of cell-penetrating peptides. Biochemistry 2004; 43: 3471-89.
50. Yang ST, Zaitseva E, Chernomordik LV, Melikov K. Cellpenetrating peptide induces leaky fusion of liposomes containing late endosome-specific anionic lipid. Biophys J 2010; 99: 2525-33.
51. Deshayes S, Gerbal-Chaloin S, Morris MC, et al. On the mechanism of non-endosomial peptide-mediated cellular delivery of nucleic acids. Biochim Biophys Acta 2004; 1667: 141-7.
52. Paulo CS, Pires das Neves R, Ferreira LS. Nanoparticles for intracellular-targeted drug delivery. Nanotechnology 2011; 22: 494002.
53. Tseng YC, Huang L. Self-assembled lipid nanomedicines for siRNA tumor targeting. J Biomed Nanotechnol 2009; 5: 351-63.
54. Morris MC, Deshayes S, Heitz F, Divita G. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell 2008; 100: 201-17.
55. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005; 62: 1839-49.
56. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 2004; 126: 9506-7.
57. Ziegler A. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev 2008; 60: 580-97.
58. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of argininerich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004; 10: 1011-22.
59. Bayer N, Schober D, Prchla E, Murphy RF, Blaas D, Fuchs R. Effect of bafilomycin A1 and nocodazole on endocytic transport in HeLa cells: implications for viral uncoating and infection. J Virol 1998; 72: 9645-55.
60. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10: 310-5.
61. de Toledo M, Senic-Matuglia F, Salamero J, et al. The GTP/GDP cycling of rho GTPase TCL is an essential regulator of the early endocytic pathway. Mol Biol Cell 2003; 14: 4846-56.
62. Via LE, Fratti RA, McFalone M, Pagan-Ramos E, Deretic D, Deretic V. Effects of cytokines on mycobacterial phagosome maturation. J Cell Sci 1998; 111: 897-905.
63. Henley JR, Krueger EW, Oswald BJ, McNiven MA. Dynaminmediated internalization of caveolae. J Cell Biol 1998; 141: 85-99.
64. Torgersen ML, Skretting G, van Deurs B, Sandvig K. Internalization of cholera toxin by different endocytic mechanisms. J Cell Sci 2001; 114: 3737-47.
65. Broeck DV, Lagrou AR, De Wolf MJ. Distinct role of clathrinmediated endocytosis in the functional uptake of cholera toxin. Acta Biochim Pol 2007; 54: 757-67.
66. Tran D, Carpentier JL, Sawano F, Gorden P, Orci L. Ligands internalized through coated or noncoated invaginations follow a common intracellular pathway. Proc Natl Acad Sci USA 1987; 84: 7957-61.
67. Couchman JR. Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 2003; 4: 926-37.
68. Deshayes S, Plénat T, Charnet P, Divita G, Molle G, Heitz F. Formation of transmembrane ionic channels of primary amphipathic cell-penetrating peptides. Consequences on the mechanism of cell penetration. Biochim Biophys Acta 2006; 1758: 1846-51.
69. Henriques ST, Castanho MA. Translocation or membrane disintegration? Implication of peptide-membrane interactions in pep-1 activity. J Pept Sci 2008; 14: 482-7.
70. Palm-Apergi C, Lorents A, Padari K, Pooga M, Hällbrink M. The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J 2009; 23: 214-23.
71. McNeil PL, Steinhardt RA. Plasma membrane disruption: repair, prevention, adaptation. Annu Rev Cell Dev Biol 2003; 19: 697-731.